Halozyme Therapeutics Stock Price, News & Analysis (NASDAQ:HALO)

$18.86 0.62 (3.40 %)
(As of 11/24/2017 02:34 AM ET)
Previous Close$18.24
Today's Range$18.29 - $18.95
52-Week Range$9.68 - $19.37
Volume895,059 shs
Average Volume1.42 million shs
Market Capitalization$2.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:HALO
CUSIP40637H10
Phone+1-858-7948889

Debt

Debt-to-Equity Ratio2.01%
Current Ratio3.46%
Quick Ratio3.37%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.69 million
Price / Sales18.30
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book36.98

Profitability

Trailing EPS($0.68)
Net Income$-103,020,000.00
Net Margins-53.17%
Return on Equity-892.57%
Return on Assets-29.67%

Miscellaneous

Employees259
Outstanding Shares142,360,000

Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.06 by $0.04. The biopharmaceutical company earned $63.73 million during the quarter, compared to the consensus estimate of $58.95 million. Halozyme Therapeutics had a negative return on equity of 892.57% and a negative net margin of 53.17%. The firm's quarterly revenue was up 100.1% on a year-over-year basis. During the same period last year, the business posted ($0.23) earnings per share. View Halozyme Therapeutics' Earnings History.

Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?

7 brokerages have issued 1 year price objectives for Halozyme Therapeutics' shares. Their forecasts range from $7.00 to $29.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $18.00 in the next year. View Analyst Ratings for Halozyme Therapeutics.

Who are some of Halozyme Therapeutics' key competitors?

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:

  • Connie L. Matsui, Chairman of the Board (Age 63)
  • Helen I Torley, President, Chief Executive Officer, Director (Age 54)
  • Laurie D. Stelzer, Chief Financial Officer, Senior Vice President (Age 49)
  • Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel (Age 60)
  • Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer (Age 45)
  • Jean-Pierre Bizzari M.D., Independent Director (Age 62)
  • James M. Daly, Independent Director (Age 55)
  • Jeffrey William Henderson, Independent Director (Age 52)
  • Kenneth J. Kelley, Independent Director (Age 57)
  • Randal J. Kirk, Independent Director (Age 63)

Who owns Halozyme Therapeutics stock?

Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Third Security LLC (12.40%), Iridian Asset Management LLC CT (7.05%), First Eagle Investment Management LLC (4.54%), JPMorgan Chase & Co. (2.02%), Bank of New York Mellon Corp (1.48%) and Pictet Asset Management Ltd. (1.41%). View Institutional Ownership Trends for Halozyme Therapeutics.

Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Third Security LLC, First Eagle Investment Management LLC, Iridian Asset Management LLC CT, Chicago Equity Partners LLC, NJ State Employees Deferred Compensation Plan, Candriam Luxembourg S.C.A., Commonwealth Equity Services Inc and Wells Fargo & Company MN. View Insider Buying and Selling for Halozyme Therapeutics.

Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Artisan Partners Limited Partnership, Pictet Asset Management Ltd., Granite Investment Partners LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., American Century Companies Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy Halozyme Therapeutics stock?

Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of Halozyme Therapeutics stock can currently be purchased for approximately $18.86.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.68 billion and generates $146.69 million in revenue each year. The biopharmaceutical company earns $-103,020,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Halozyme Therapeutics employs 259 workers across the globe.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 Sorrento Valley Rd, SAN DIEGO, CA 92121-1345, United States. The biopharmaceutical company can be reached via phone at +1-858-7948889 or via email at [email protected]


MarketBeat Community Rating for Halozyme Therapeutics (HALO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Halozyme Therapeutics (NASDAQ:HALO)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.272.362.502.60
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.13$17.00$15.33$15.64
Price Target Upside: 5.60% downside2.69% downside24.76% upside22.08% upside

Consensus Price Target History for Halozyme Therapeutics (NASDAQ:HALO)

Price Target History for Halozyme Therapeutics (NASDAQ:HALO)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/22/2017Barclays PLCDowngradeOverweight -> Hold$16.00 -> $19.00N/AView Rating Details
11/8/2017Canaccord GenuityBoost Price TargetBuy$17.00 -> $19.00N/AView Rating Details
11/8/2017BMO Capital MarketsBoost Price TargetMarket Perform$15.00 -> $18.00N/AView Rating Details
10/16/2017Piper Jaffray CompaniesBoost Price TargetOverweight -> Overweight$26.00 -> $29.00N/AView Rating Details
9/15/2017Deutsche Bank AGBoost Price TargetBuy$20.00LowView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingUnderperform$6.75 -> $7.00HighView Rating Details
1/6/2017Citigroup Inc.DowngradeBuy -> NeutralN/AView Rating Details
9/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Halozyme Therapeutics (NASDAQ:HALO)

Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Earnings History by Quarter for Halozyme Therapeutics (NASDAQ HALO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017$0.06$0.02$58.95 million$63.73 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.25)($0.23)$31.76 million$33.80 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.26)$30.79 million$29.60 millionViewListenView Earnings Details
2/28/2017Q416($0.30)($0.21)$37.94 million$39.00 millionViewListenView Earnings Details
11/7/2016Q316($0.27)($0.23)$34.43 million$31.90 millionViewListenView Earnings Details
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.18)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
2017 EPS Consensus Estimate: ($0.24)
2018 EPS Consensus Estimate: ($1.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171$0.57$0.57$0.57
Q1 20181($0.25)($0.25)($0.25)
Q2 20181($0.26)($0.26)($0.26)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ HALO)

Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 83.12%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ HALO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Halozyme Therapeutics (NASDAQ HALO)

Source:
DateHeadline
Barrons After Hours: Halozyme Jumps, WPX Energy Slumps, Delphi Technologies FallsBarron's After Hours: Halozyme Jumps, WPX Energy Slumps, Delphi Technologies Falls
finance.yahoo.com - November 23 at 1:13 AM
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options - NasdaqImplied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options - Nasdaq
www.nasdaq.com - November 22 at 8:11 PM
Halozyme Therapeutics, Inc. (HALO) Lowered to "Hold" at Barclays PLCHalozyme Therapeutics, Inc. (HALO) Lowered to "Hold" at Barclays PLC
www.americanbankingnews.com - November 22 at 5:10 PM
Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Acorda TherapeuticsToday’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Acorda Therapeutics
finance.yahoo.com - November 21 at 8:10 AM
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock OptionsImplied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
finance.yahoo.com - November 20 at 7:51 PM
Halozyme Therapeutics To Participate In Upcoming Healthcare ConferencesHalozyme Therapeutics To Participate In Upcoming Healthcare Conferences
finance.yahoo.com - November 16 at 3:12 PM
Biotech Stocks on Investors Radar -- Endocyte, Editas Medicine, Halozyme Therapeutics, and IlluminaBiotech Stocks on Investors' Radar -- Endocyte, Editas Medicine, Halozyme Therapeutics, and Illumina
www.bizjournals.com - November 13 at 9:18 AM
Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology,Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology,
www.nasdaq.com - November 13 at 9:18 AM
Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences – Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - November 13 at 9:18 AM
Halozyme Therapeutics, Inc. 2017 Q3 - Results - Earnings Call SlidesHalozyme Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 12 at 10:08 AM
Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint InhibitorsHalozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors
finance.yahoo.com - November 12 at 10:08 AM
Investors Purchase High Volume of Put Options on Halozyme Therapeutics (HALO)Investors Purchase High Volume of Put Options on Halozyme Therapeutics (HALO)
www.americanbankingnews.com - November 12 at 4:04 AM
Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors - PR Newswire (press release)Halozyme To Present Nonclinical Data At SITC 2017 Supporting Combination Of PEGPH20 With Checkpoint Inhibitors - PR Newswire (press release)
www.prnewswire.com - November 11 at 5:35 AM
Halozyme To Present Nonclinical Data At SITC 2017 Supporting ... - PR Newswire (press release)Halozyme To Present Nonclinical Data At SITC 2017 Supporting ... - PR Newswire (press release)
www.prnewswire.com - November 11 at 5:35 AM
Equities Analysts Issue Forecasts for Halozyme Therapeutics, Inc.s FY2017 Earnings (HALO)Equities Analysts Issue Forecasts for Halozyme Therapeutics, Inc.'s FY2017 Earnings (HALO)
www.americanbankingnews.com - November 10 at 7:40 AM
Jefferies Group Comments on Halozyme Therapeutics, Inc.s Q1 2018 Earnings (HALO)Jefferies Group Comments on Halozyme Therapeutics, Inc.'s Q1 2018 Earnings (HALO)
www.americanbankingnews.com - November 9 at 11:46 AM
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High - Motley FoolWhy Halozyme Therapeutics, Inc. Deserves Its 52-Week High - Motley Fool
www.fool.com - November 9 at 6:27 AM
 Analysts Expect Halozyme Therapeutics, Inc. (HALO) Will Announce Quarterly Sales of $108.70 Million Analysts Expect Halozyme Therapeutics, Inc. (HALO) Will Announce Quarterly Sales of $108.70 Million
www.americanbankingnews.com - November 9 at 4:48 AM
Halozyme Therapeutics, Inc. (HALO) Announces  Earnings Results, Misses Estimates By $0.04 EPSHalozyme Therapeutics, Inc. (HALO) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week HighWhy Halozyme Therapeutics, Inc. Deserves Its 52-Week High
www.fool.com - November 8 at 3:35 PM
Canaccord Genuity Increases Halozyme Therapeutics, Inc. (HALO) Price Target to $19.00Canaccord Genuity Increases Halozyme Therapeutics, Inc. (HALO) Price Target to $19.00
www.americanbankingnews.com - November 8 at 3:10 PM
Halozyme Reports Third Quarter 2017 Results - PR Newswire (press release)Halozyme Reports Third Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - November 8 at 8:47 AM
Halozyme Therapeutics (HALO) CEO Dr. Helen Torley on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaHalozyme Therapeutics' (HALO) CEO Dr. Helen Torley on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 8:47 AM
Halozyme Therapeutics, Inc. to Host Earnings CallHalozyme Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 8:47 AM
Halozyme Reports Third Quarter 2017 ResultsHalozyme Reports Third Quarter 2017 Results
finance.yahoo.com - November 8 at 8:47 AM
Halozyme Therapeutics beats 3Q profit forecastsHalozyme Therapeutics beats 3Q profit forecasts
finance.yahoo.com - November 8 at 8:47 AM
Edited Transcript of HALO earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of HALO earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 8:47 AM
Zacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) to Announce -$0.12 Earnings Per ShareZacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) to Announce -$0.12 Earnings Per Share
www.americanbankingnews.com - November 7 at 5:40 PM
Halozyme Therapeutics, Inc. (HALO) Receives Consensus Recommendation of "Hold" from AnalystsHalozyme Therapeutics, Inc. (HALO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 5 at 5:34 PM
Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings? - NasdaqShould You Buy Halozyme Therapeutics (HALO) Ahead of Earnings? - Nasdaq
www.nasdaq.com - November 5 at 2:09 AM
Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings?Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings?
finance.yahoo.com - November 3 at 9:42 PM
Halozyme Therapeutics (HALO) Phase 3 Study of Subcutanous ... - StreetInsider.comHalozyme Therapeutics (HALO) Phase 3 Study of Subcutanous ... - StreetInsider.com
www.streetinsider.com - November 2 at 3:47 AM
Halozyme Therapeutics (HALO) Phase 3 Study of Subcutanous Daratumumab Initiated Using its ENHANZE TechnologyHalozyme Therapeutics (HALO) Phase 3 Study of Subcutanous Daratumumab Initiated Using its ENHANZE Technology
www.streetinsider.com - October 31 at 8:51 PM
BRIEF-Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of DarzalexBRIEF-Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
www.reuters.com - October 31 at 8:51 PM
Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozymes ENHANZE TechnologyPhase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology
finance.yahoo.com - October 31 at 8:51 PM
Halozyme Therapeutics, Inc. (HALO) Set to Announce Quarterly Earnings on TuesdayHalozyme Therapeutics, Inc. (HALO) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 11:34 AM
ETFs with exposure to Halozyme Therapeutics, Inc. : October 30, 2017ETFs with exposure to Halozyme Therapeutics, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 3:15 PM
Halozyme Therapeutics (HALO) Announces First Gastric Cancer Patient Dosed In Clinical Trial Collaboration ... - StreetInsider.comHalozyme Therapeutics (HALO) Announces First Gastric Cancer Patient Dosed In Clinical Trial Collaboration ... - StreetInsider.com
www.streetinsider.com - October 26 at 9:45 AM
Commit To Buy Halozyme Therapeutics At $12, Earn 7.9% Using Options - NasdaqCommit To Buy Halozyme Therapeutics At $12, Earn 7.9% Using Options - Nasdaq
www.nasdaq.com - October 26 at 9:45 AM
Halozyme Therapeutics (HALO) Announces First Gastric Cancer Patient Dosed In ...Halozyme Therapeutics (HALO) Announces First Gastric Cancer Patient Dosed In ...
www.streetinsider.com - October 25 at 3:25 AM
First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozymes PEGPH20 In Combination With Anti-PDL1 ImmunotherapyFirst Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozyme's PEGPH20 In Combination With Anti-PDL1 Immunotherapy
finance.yahoo.com - October 25 at 3:25 AM
ETFs with exposure to Halozyme Therapeutics, Inc. : October 18, 2017ETFs with exposure to Halozyme Therapeutics, Inc. : October 18, 2017
finance.yahoo.com - October 19 at 1:41 AM
3 Drug Stocks Hitting 52-Week Highs: Are They Buys?3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
finance.yahoo.com - October 17 at 3:18 PM
Halozyme Therapeutics (HALO) Commences Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma & Gallbladder Cancer PatientsHalozyme Therapeutics (HALO) Commences Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma & Gallbladder Cancer Patients
www.streetinsider.com - October 16 at 4:01 PM
Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer PatientsHalozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients
finance.yahoo.com - October 16 at 4:01 PM
Piper Jaffray Companies Boosts Halozyme Therapeutics, Inc. (HALO) Price Target to $29.00Piper Jaffray Companies Boosts Halozyme Therapeutics, Inc. (HALO) Price Target to $29.00
www.americanbankingnews.com - October 16 at 11:06 AM
Halozyme Therapeutics, Inc. (HALO) Sees Significant Decrease in Short InterestHalozyme Therapeutics, Inc. (HALO) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 13 at 1:32 AM
Halozyme Therapeutics, Inc. (HALO) Given Consensus Recommendation of "Hold" by BrokeragesHalozyme Therapeutics, Inc. (HALO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 11 at 8:08 PM
Halozyme to Host Third Quarter 2017 Financial Results Conference CallHalozyme to Host Third Quarter 2017 Financial Results Conference Call
finance.yahoo.com - October 10 at 6:49 PM
Halozyme Therapeutics, Inc. (HALO) Cut to "Hold" at Zacks Investment ResearchHalozyme Therapeutics, Inc. (HALO) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 6 at 11:14 PM

Social Media

Financials

Chart

Halozyme Therapeutics (NASDAQ HALO) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.